Announcement of Resolutions of the 18th (Provisional) Meeting of the 11th Board of Directors of the Company
Securities code: 600572 Securities abbreviation: Conba Announcement number: Lin 2026-038 Zhejiang Conba Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 18th (Extraordinary) Meeting of the 11th Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The 18th (temporary) meeting of the 11th Board of Directors of Zhejiang Conba Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" and "Conba") was held by communication on June 17, 2026. The meeting notice will be sent to all directors in writing and via email on June 12, 2026. Nine directors were supposed to participate in the deliberation and voting at the meeting, and 9 directors actually participated in the deliberation and voting. The meeting was held in compliance with the provisions of the Company Law and the Articles of Association.
The meeting reviewed relevant proposals and passed the following resolutions by written vote:
- The "Proposal on Conba's "15th Five-Year Plan" Strategic Plan" was reviewed and approved. Voting results: 9 votes in favor; 0 votes against; 0 abstentions.
The vision blueprint and overall ideas of Conba’s “15th Five-Year Plan” strategic plan are as follows:
Vision Blueprint: Become a trusted and respected leading pharmaceutical and health enterprise with both inheritance and innovation - leading the industry, leading value and leading growth.
The overall idea: "Inheriting the essence, keeping integrity and innovation" as the basic guideline, adhering to the mission of "devoting sincerity and love to human health", adhering to the two-wheel drive of connotative growth and extensional expansion, adhering to innovation and leadership to forge new productivity, and adhering to the two-way empowerment and coordinated development of internal and external business. Through the implementation of the "Eight Special Projects" strategic initiatives, we have achieved the creation of "Four Core Competencies", driven the improvement of both efficiency and value of Conba, and become a trusted and respected leading pharmaceutical and health enterprise.
- The "Proposal on Adjusting the Stock Option Exercise Price of the 2022 Stock Option Incentive Plan" was reviewed and approved. Voting results: 7 votes in favor, 2 votes to avoid, 0 votes against, and 0 abstentions. (For details, please refer to Company Lin No. 2026-039 "Announcement on Adjusting the Stock Option Exercise Price of the 2022 Stock Option Incentive Plan" published on the same day in the "Shanghai Securities News", "China Securities News", "Securities Times" and the Shanghai Stock Exchange website http://www.sse.com.cn)
In accordance with the relevant provisions of the China Securities Regulatory Commission's "Equity Incentive Management Measures for Listed Companies" and "Zhejiang Conba Pharmaceutical Co., Ltd. 2022 Stock Option Incentive Plan (Draft)" and the authorization of relevant resolutions of the company's second extraordinary shareholders' meeting in 2022, it is agreed that after the company completes the implementation of the 2025 annual equity distribution plan (a cash dividend of 1.50 yuan for every 10 shares), the company's 2022 The exercise price of stock options granted for the first time under the annual stock option incentive plan was adjusted from 3.63 yuan/share to 3.48 yuan/share, and the exercise price of reserved stock options granted was adjusted from 4.92 yuan/share to 4.77 yuan/share.
When the company's board of directors reviewed this proposal, because directors Wu Luwen and Wang Taofang were incentive targets of the "Zhejiang Conba Pharmaceutical Co., Ltd. 2022 Stock Option Incentive Plan (Draft)", they avoided voting on the proposal, and the remaining seven directors participated in the vote.
- The "Proposal on Adjustment of Directors of the Company" was reviewed and approved. Voting results: 9 votes in favor; 0 votes against; 0 abstentions. (For details, please refer to the "Announcement on the Resignation of the Company's Directors and the By-Election of Directors" No. 2026-040 published in the "Shanghai Securities News", "China Securities News", "Securities Times" and the Shanghai Stock Exchange website http://www.sse.com.cn on the same day)
In view of the resignation of Mr. Ye Jianfeng as a director of the company and the corresponding positions on the board of directors, it was agreed to add Mr. Shen Qi as a non-independent director candidate for the 11th board of directors of the company, with a term starting from the date of review and approval by the shareholders' meeting and ending with the expiration of the term of the 11th board of directors. Mr. Shen Qi’s resume is as follows:
Shen Qi, Chinese, male, born in 1982, holds a postgraduate degree from Zhejiang University, a Master of Engineering, and is a member of the Communist Party of China. He once served as investment director of Hangzhou Qingyong Capital Management Co., Ltd., deputy investment director of Shenzhen Xiaoniu Investment Management Co., Ltd., investment director of Zhejiang Jitai Investment Co., Ltd., deputy general manager of the investment banking department of Zhejiang Huiyuan Investment Management Co., Ltd., deputy general manager of the investment banking department and deputy general manager of the strategy and industrial investment department of Zhejiang Medical and Health Industry Group Co., Ltd. , deputy general manager of the Operation Management Department (in charge of work), general manager of the Strategy and Investment Management Department, vice president and investment director of Zhejiang Conba Pharmaceutical Co., Ltd., currently deputy general manager of the Strategic Management Department (Science and Technology Innovation Center) of Zhejiang International Trade Group Co., Ltd., director of Zhejiang Industrial Investment Group Co., Ltd., and director of Zhejiang Oriental Holding Group Co., Ltd.
The company's board of directors, as the nominee for additional non-independent director candidates for the 11th session of the board of directors, has reviewed and found that Mr. Shen Qi has no affiliation with the company or its directors, senior managers, actual controllers and shareholders holding more than 5% of the shares. There is no situation in which he is prohibited from serving as a director of a listed company under the Company Law, the China Securities Regulatory Commission and the stock exchange. He has not been punished by the China Securities Regulatory Commission and other relevant departments or stock exchanges, and he does not hold shares of the company. After verification, Mr. Shen Qi was not the person subject to execution for breach of trust.
This proposal has been reviewed and approved unanimously at the third special meeting of independent directors of the company's eleventh board of directors in 2026.
This proposal still needs to be submitted to the company's shareholders' meeting for review.
- The "Proposal on Convening the Company's Second Extraordinary Shareholders' Meeting in 2026" was reviewed and approved. Voting results: 9 votes in favor; 0 votes against; 0 abstentions. (For details, please refer to the "Notice on Convening the Company's Second Extraordinary Shareholders' Meeting in 2026" No. 2026-041 published on the same day in the "Shanghai Securities News", "China Securities News", "Securities Times" and the Shanghai Stock Exchange website http://www.sse.com.cn)
It was decided to hold the company's second extraordinary shareholders' meeting in 2026 on July 3, 2026, in the conference room on the 2nd floor of the Conba Center, No. 568 Binkang Road, Binjiang District, Hangzhou, through a combination of on-site meetings and online voting. The agenda of the meeting is: to review the "Proposal on Adding Directors of the Company."
Other relevant matters of the meeting will be specified in the notice convening the shareholders' meeting.
Announcement is hereby made.
Board of Directors of Zhejiang Conba Pharmaceutical Co., Ltd.
June 18, 2026